Head to Head Analysis: Sanofi (NASDAQ:SNY) versus Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Earnings and Valuation

This table compares Recordati Industria Chimica E Farmaceutica and Sanofi”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.04	$501.92 million	$2.80	20.71
Sanofi	$49.35 billion	2.09	$8.84 billion	$1.91	22.24

Sanofi has higher revenue and earnings than Recordati Industria Chimica E Farmaceutica. Recordati Industria Chimica E Farmaceutica is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Recordati Industria Chimica E Farmaceutica and Sanofi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	1	3.00
Sanofi	1	10	3	2	2.38

Sanofi has a consensus price target of $49.50, suggesting a potential upside of 16.53%. Given Sanofi’s higher possible upside, analysts plainly believe Sanofi is more favorable than Recordati Industria Chimica E Farmaceutica.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Sanofi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	18.38%	33.73%	12.76%
Sanofi	8.66%	14.19%	7.95%

Institutional and Insider Ownership

14.0% of Sanofi shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Recordati Industria Chimica E Farmaceutica has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Summary

Sanofi beats Recordati Industria Chimica E Farmaceutica on 9 of the 15 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.